AVROBIO Inc

NASDAQ AVRO

Data sourced from iex and EODHD
Download Data

AVROBIO Inc Retention Ratio for the year ending December 31, 2023: -31.85%

AVROBIO Inc Retention Ratio is -31.85% for the year ending December 31, 2023. The retention ratio, also known as the plowback ratio, measures the proportion of a company's earnings that are retained after paying dividends. It is calculated by dividing the net income minus dividends paid by the net income. This ratio indicates the percentage of earnings that are reinvested back into the company rather than being distributed to shareholders as dividends. A higher retention ratio suggests a higher level of reinvestment, indicating potential future growth opportunities.
  • AVROBIO Inc Retention Ratio for the year ending December 31, 2021 was 112.65%.
NASDAQ: AVRO

AVROBIO Inc

CEO Mr. Geoff MacKay BSc
IPO Date June 21, 2018
Location United States
Headquarters Building 300, Cambridge, MA, United States, 02139
Employees 13
Sector Healthcare
Industry Biotechnology
Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email